Cognitive Behavioral Therapy
Conditions
Brief summary
Background: Neuropsychiatric conditions, such as insomnia, anxiety, depression, and pain are the most common symptoms experienced by nurses after acute infection of COVID-19. Although medication can assist nurses to improve these symptoms simultaneously in a short period of time, they are at risk of overuse of benzodiazepine hypnotics. Previous research supports the usefulness of cognitive behavioral therapy for insomnia (CBT-I) as self-management strategies in adults with insomnia, anxiety, depression, and pain. However, their effects on post COVID-19 condition have not been researched, and no previous head-to-head study compared the effects on these two approaches on insomnia and neuropsychiatric symptoms. Aim: To investigate the effects of CBT-I on insomnia, anxiety, depression, and pain in nurses with post COVID-19 condition. Methods: In this two-arm, parallel randomized controlled trial, 100 participants will be 1:1 randomly assigned to one of two groups (CBT-I and control). The intervention phase will last 6 weeks, followed by a three-month follow-up. Primary outcomes are insomnia severity and sleep quality, whereas anxiety, depression, pain, and health-related quality of life are secondary outcomes. These variables will be assessed before and after the intervention, and at 1, 2, and 3 months after the end of the intervention. Additionally, discontinuing benzodiazepine hypnotics will be measured at 3 months after the end of the intervention. Discussion: This study will provide evidence of the effects of CBT-I on improving insomnia, anxiety, depression, and pain among nurses with post COVID-19 condition. Results could also enhance means by which to discontinue benzodiazepine hypnotics.
Interventions
6 weeks cognitive behavioral therapy
Sponsors
Study design
Eligibility
Inclusion criteria
* nurses with post COVID-19 condition
Exclusion criteria
* history of sleep apnea, narcolepsy, pregnant, seizure, with pacemaker
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| insomnia severity | 20 weeks | measured by Insomnia Severity Index before and after the intervention, and at 1, 2, and 3 months after the end of the intervention |
| sleep quality | 20 weeks | measured by Pittsburgh Sleep Quality Index |
| sleep efficiency | 20 weeks | measured by Fitbit Charge 5 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| anxiety | 20weeks | measured by Generalized Anxiety Disorder 7-Item |
| depression | 20weeks | measured by Patient Health Questionnaire 9 item |
| health-related quality of life | 20weeks | measured by 36-Item Short Form Health Survey |